论文部分内容阅读
目的研究分析奥沙利铂联合表柔吡星及5-氟尿嘧啶(5-Fu)对晚期胃癌患者的近远期疗效及安全性。方法 120例晚期胃癌患者,随机分为观察组和对照组,每组60例。对照组采用亚叶酸钙、5-Fu及顺铂联合治疗,观察组则采用5-Fu、奥沙利铂及表柔吡星联合治疗,对比两组患者治疗后毒副反应及生活质量评分。结果观察组患者治疗后毒副反应显著少于对照组,生活质量评分显著高于对照组,差异有统计学意义(P<0.05)。结论奥沙利铂联合表柔吡星及5-Fu对晚期胃癌患者的近远期治疗效果显著且安全性较高,值得临床推广。
Objective To study the short-term and long-term efficacy and safety of oxaliplatin combined with epirubicin and 5-fluorouracil in patients with advanced gastric cancer. Methods 120 patients with advanced gastric cancer were randomly divided into observation group and control group, 60 cases in each group. The control group was treated with leucovorin, 5-Fu and cisplatin. The observation group was treated with 5-Fu, oxaliplatin and droperidol, and the side effects and quality of life scores were compared between the two groups after treatment. Results The observation group had significantly fewer side effects after treatment, and the quality of life scores were significantly higher than those in the control group (P <0.05). Conclusion The combination of oxaliplatin with epirubicin and 5-Fu in the treatment of patients with advanced gastric cancer has obvious short-term and long-term therapeutic effects and is worthy of clinical promotion.